KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Gains from Investment Securities: 2013-2025

Historic Gains from Investment Securities for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to $807,000.

  • Travere Therapeutics' Gains from Investment Securities rose 146.04% to $807,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 80.28%. This contributed to the annual value of -$7.9 million for FY2024, which is 319.08% down from last year.
  • Latest data reveals that Travere Therapeutics reported Gains from Investment Securities of $807,000 as of Q3 2025, which was up 192.12% from -$876,000 recorded in Q2 2025.
  • Travere Therapeutics' Gains from Investment Securities' 5-year high stood at $13.9 million during Q3 2021, with a 5-year trough of -$40.4 million in Q4 2021.
  • Over the past 3 years, Travere Therapeutics' median Gains from Investment Securities value was $328,000 (recorded in 2024), while the average stood at -$237,091.
  • In the last 5 years, Travere Therapeutics' Gains from Investment Securities plummeted by 1,789.67% in 2021 and then spiked by 531.04% in 2025.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Gains from Investment Securities stood at -$40.4 million in 2021, then surged by 109.97% to $4.0 million in 2022, then tumbled by 154.30% to -$2.2 million in 2023, then slumped by 33.49% to -$2.9 million in 2024, then soared by 146.04% to $807,000 in 2025.
  • Its Gains from Investment Securities stands at $807,000 for Q3 2025, versus -$876,000 for Q2 2025 and $1.6 million for Q1 2025.